LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced the pricing of its underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $18.25 per share. The gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by uniQure, are expected to be $91,250,000. All ordinary shares to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about October 27, 2017, subject to the satisfaction of customary closing conditions.

Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering. Chardan is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated gene therapy technology platform to advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases.